Patents by Inventor James M. Veal

James M. Veal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF QPCTL AND QPCT
    Publication number: 20240101544
    Abstract: Provided herein are compounds of formula (I) and formula (II) that are inhibitors of QPCTL and QPCT: Also provided are pharmaceutical compositions comprising the compounds, and methods for using the compounds for the treatment of disease.
    Type: Application
    Filed: July 20, 2023
    Publication date: March 28, 2024
    Inventors: James M. Veal, Jeffrey A. Stafford, Donald S. Karanewsky, Shyama Herath
  • Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG
    Patent number: 11939335
    Abstract: Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: March 26, 2024
    Assignee: 858 THERAPEUTICS, INC.
    Inventors: James M. Veal, Jeffrey A. Stafford, Donald S. Karanewsky, Shyama Herath
  • INHIBITORS OF PARG
    Publication number: 20230374022
    Abstract: Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.
    Type: Application
    Filed: May 19, 2023
    Publication date: November 23, 2023
    Inventors: James M. VEAL, Jeffrey A. STAFFORD, Donald S. KARANEWSKY, Shyama HERATH
  • Chemical compounds as inhibitors of interleukin-1 activity
    Patent number: 11702428
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: July 18, 2023
    Assignee: Genentech, Inc.
    Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride
  • Sulfonylurea compounds as inhibitors of interleukin-1 activity
    Patent number: 11560391
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: January 24, 2023
    Assignee: Genentech, Inc.
    Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride, Richard M. Pastor, Steven Thomas Staben, Craig Stivala, Matthew Volgraf
  • CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20220306649
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: March 3, 2022
    Publication date: September 29, 2022
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE
  • CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20210395268
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 25, 2021
    Publication date: December 23, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE
  • SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20210261568
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 26, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF
  • Chemical compounds as inhibitors of interleukin-1 activity
    Patent number: 11040985
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: June 22, 2021
    Assignee: Genentech, Inc.
    Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride
  • Bromodomain inhibitors
    Patent number: 10807982
    Abstract: The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: October 20, 2020
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Michael John Bennett, Juan Manual Betancort, Amogh Boloor, Stephen W. Kaldor, Jeffrey Alan Stafford, James M. Veal
  • BROMODOMAIN INHIBITORS
    Publication number: 20200071332
    Abstract: The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
    Type: Application
    Filed: November 4, 2019
    Publication date: March 5, 2020
    Applicant: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Michael John Bennett, Juan Manual Betancort, Amogh Boioor, Stephen W. Kaidor, Jeffrey Alan Stafford, James M. Veal
  • CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20190337965
    Abstract: The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE
  • 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives
    Patent number: 8871767
    Abstract: Disclosed are compounds of formula (I): where X, Y, X, A, R1, R2, and R3 are defined herein. Also disclosed are pharmaceutically acceptable salts of the compounds, compositions containing the compounds, and methods of using the compounds to treat, e.g., cancer.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: October 28, 2014
    Assignee: Hengrui (USA) Ltd.
    Inventors: Robert N. Atkinson, Andy J. Ommen, James M. Veal, Kenneth H. Huang, Emilie D. Smith
  • ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES
    Publication number: 20130085157
    Abstract: This disclosure relates to compounds, compositions and methods for the treatment of various disorders. In particular, the disclosure relates to thiazolotriazole and thiazoloimidazole compounds which agonize the activity of the protein TGR5.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 4, 2013
    Inventors: Emilie D. Smith, Mark E. Fitzgerald, Rong Jiang, Robert N. Atkinson, James M. Veal, Kenneth H. Huang
  • 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES
    Publication number: 20120178751
    Abstract: Disclosed are compounds of formula (I): where X, Y, X, A, R1, R2, and R3 are defined herein. Also disclosed are pharmaceutically acceptable salts of the compounds, compositions containing the compounds, and methods of using the compounds to treat, e.g., cancer.
    Type: Application
    Filed: December 22, 2011
    Publication date: July 12, 2012
    Inventors: Robert N. Atkinson, Andy J. Ommen, James M. Veal, Kenneth H. Huang, Emilie D. Smith
  • SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES
    Publication number: 20120077814
    Abstract: The disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof, compositions containing these compounds, and methods of using these compounds in a variety applications, such as treatment of diseases or disorders associated with E1 type activating enzymes, and with Nedd8 activating enzyme (NAE) in particular.
    Type: Application
    Filed: September 12, 2011
    Publication date: March 29, 2012
    Inventors: Zhong Wang, Emilie D. Smith, James M. Veal, Kenneth H. Huang, Robert N. Atkinson, Rong Jiang